FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. - Wikidata - wikimedia - TriplyDB

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

http://www.wikidata.org/entity/Q34117524

about

HIV-1 prophylactic vaccines: state of the art Immune correlates of vaccine protection against HIV-1 acquisition Vaccine-Elicited Mucosal and Systemic Antibody Responses Are Associated with Reduced Simian Immunodeficiency Viremia in Infant Rhesus Macaques Systems serology for evaluation of HIV vaccine trials.Antiviral Functions of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific IgG Antibodies: Effects of Antiretroviral Therapy and Implications for Therapeutic HIV-1 Vaccine Design.V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.Short communication: Fc gamma receptors IIa and IIIa genetic polymorphisms do not predict HIV-1 disease progression in Kenyan women.Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life.Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification.Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus.Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates.FCGR2C Polymorphisms Associated with HIV-1 Vaccine Protection Are Linked to Altered Gene Expression of Fc-γ Receptors in Human B Cells Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses New prospects for a preventive HIV-1 vaccine.FCGR2A and FCGR3A Genotypes in Human Immunodeficiency Virus Mother-to-Child Transmission.Breakthrough Virus Neutralization Resistance as a Correlate of Protection in a Nonhuman Primate Heterologous Simian Immunodeficiency Virus Vaccine Challenge Study.Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models.Augmented case-only designs for randomized clinical trials with failure time endpoints.HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition.The role of Fc receptors in HIV prevention and therapy.Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection.A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes.Fcγ receptors: genetic variation, function, and disease.Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects.Predicting Overall Vaccine Efficacy in a New Setting by Re-Calibrating Baseline Covariate and Intermediate Response Endpoint Effect Modifiers of Type-Specific Vaccine Efficacy.HIV antibodies for treatment of HIV infection.Complex immune correlates of protection in HIV-1 vaccine efficacy trials.Antibody Functional Assays as Measures of Fc Receptor-Mediated Immunity to HIV - New Technologies and their Impact on the HIV Vaccine Field.Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults.Variability at the FCGR locus: characterization in Black South Africans and evidence for ethnic variation in and out of Africa.Identifying optimal biomarker combinations for treatment selection through randomized controlled trials.Case-only approach to identifying markers predicting treatment effects on the relative risk scale.Identifying optimal biomarker combinations for treatment selection via a robust kernel method.Non-neutralizing antibody functions for protection and control HIV in humans and SIV and SHIV in non-human primates.Non-Neutralizing Antibodies Directed against HIV and Their Functions.Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome.Discrimination of FCGR2B polymorphism without coamplification of FCGR2A and FCGR2C genes.FcγRIIa defunctioning polymorphism in paediatric patients with renal allograft.Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular Clones.

P2860

Q26740042-31FD438E-2953-4D56-B745-13682075282A Q26778573-0B7DB124-D493-4C0B-BA4E-682B4B75CF80 Q28830298-963A3DB7-5A8F-40FA-988D-8B6E3B92A754 Q30238729-3A3BDF7D-76BE-4A39-AA91-ED39EF0AAF40 Q33867299-BD195C8F-B21E-4D23-A7F1-D13C3DFFB222 Q33874253-16D4A8D2-044C-4875-9864-00DD33B465EA Q34540352-FE82CDE8-299D-4CF0-A460-153D1C60B26B Q35142518-B609CA6B-6DB4-431D-88BB-449E7673B366 Q35569901-52E8C335-C645-4B9A-8AEC-1C3FD1361D82 Q35823060-5C32F84C-90A9-4B89-AF50-49FDD92EFBE1 Q35834551-B59B9DDA-2D92-4B87-8FC1-B53D84DAD5DE Q35914306-43A27795-C232-42AB-BE2C-7EE2A0ED7542 Q35970342-5E13194A-EC4E-4F27-A549-BA7A491FE991 Q36118373-9E6D0E40-2DC8-483A-BF2B-78C2E83939F3 Q36223864-D9EBD9AC-10BB-47B3-940A-14F6DD4B55B9 Q36302010-A36FAAD8-494C-4C27-9D50-AAAA3C09F637 Q36334371-DAE22AFC-F28A-4CC4-AC5B-27D5C6BA2FCD Q36437672-6782F20B-6410-43E7-9D3A-28456CFE1A1D Q36730923-BC3C63CB-39A3-484C-9675-2BC43D7883FC Q37013490-A9494865-7E1E-4BF2-B298-2DA798014953 Q37113972-2689502F-23CD-4F83-AB77-AD576075AF97 Q37510242-FCC7DBB4-D686-4AF6-AD00-CB094809CADA Q37656908-083BAE4D-18CE-4121-B4E2-B62FDD4C1C32 Q38615347-BF2AE485-D43E-414F-AB9D-2B96760A2ECC Q38727815-638428FE-3567-4D09-AE27-FD9BF09E5D14 Q38982807-DFFF973A-81C1-4C05-A9BB-1C6F7847CD8A Q39108716-5C8887D5-9B52-484B-B16E-CC6A924D713A Q39108779-D0C29CC3-EF74-4477-B819-B67B503B14C5 Q39189458-809D8401-B8EF-4741-985B-37BDAA38CB1F Q40114912-4F9680E6-751E-446D-BDB4-C72808449BEA Q40205433-E7547CF6-6AE2-4565-B719-6B61BA60F9A4 Q40967594-FCF9AA80-AB77-422F-B9F2-82F72CD2D6D8 Q41993145-42E5D031-1EE3-4CE4-AA79-C342F516C190 Q42182239-0FB3C533-049D-44B6-BA10-569DC46856C0 Q42368984-7D442A70-7392-422B-91F2-2CE063928C38 Q47139556-FFCA62E9-7900-4D24-B144-E749D6935A8D Q47218587-1677263E-6BCE-4F5F-9EEE-69BAC312B0FE Q48142748-258ED093-2E9C-495D-8AB1-9C23FE8FAABA Q50255957-2DB6A3EA-836D-4FF4-B276-E2CED4E1DAC8 Q52660832-877A3F71-2373-457E-B223-70CD1D7C1A34

P2860

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

http://www.wikidata.org/entity/Q34117524

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

@ast

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

@en

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

@nl

type

label

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

@ast

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

@en

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

@nl

prefLabel

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

@ast

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

@en

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

@nl

P1433

Q34117524-899716C8-F219-4D6D-92B3-2641279C4C92

P1476

Q34117524-702C02C9-E255-4C2B-B61B-95CD2B16F23C

P2093

Q34117524-092C4C40-7700-4C0B-AC69-F06553D2CDBD

Q34117524-199DA3DF-6C03-413E-9E24-7CF5B50903F9

Q34117524-2FB95082-813B-48FC-B7C8-BB5141A48015

Q34117524-3FEC1552-7E1C-48EC-9172-E9ACA0B61E6A

Q34117524-40A254D5-145E-4B11-AFA6-58F35A5FBF6C

Q34117524-44E921FD-E834-4251-9A1F-D8E1D9A745DF

Q34117524-5255B97E-5812-42B4-9070-2B949FD58699

Q34117524-5C8F77F4-16F0-408D-BCF5-ED05DA0638EC

Q34117524-7D07A347-A2BD-4F3B-A544-1F884448619C

Q34117524-7FBEB37A-7C49-44FC-8622-4F655D85C850

P2860

Q34117524-00728FC7-A06D-49D3-80FD-1B369C6893E9

Q34117524-06470049-6D3B-4C5A-AE8B-A8ED02CDFF45

Q34117524-1E86B10E-86E6-468C-AD75-D0DCFB95B4A5

Q34117524-2370A77B-398D-4C8A-A39D-0EB705E7869B

Q34117524-2FE75865-BE04-4A40-B183-E32283410DFF

Q34117524-3612E6F2-F275-41CB-84EC-64FF9F83FBB5

Q34117524-3797BB22-25BB-463C-9CF5-A2FD9CB84C79

Q34117524-40C7B985-7CAD-4A6B-84C5-7609FB8C67D0

Q34117524-418BC3DA-9574-4539-885E-AA7D6D7A2682

Q34117524-42CC935E-2B74-44E0-9D2D-62B3C24A0286

P304

Q34117524-2647460A-74DB-4442-ACE5-D9A6850AA7E0

P31

Q34117524-D73FDA18-D819-4E6F-BF09-3B02181E0119

P356

Q34117524-F310664F-FB46-4604-9DF4-4499C4D60368

P407

Q34117524-B9E75AAA-0EE0-47C0-968F-38CE7A241668

P433

Q34117524-8753CD33-9758-4269-8B19-3D84988620EA

P478

Q34117524-A4783B07-A4CE-4416-814B-EC44CF7072E0

P50

Q34117524-5CB69E7D-2500-43B0-AD00-1ADF9A3215A5

Q34117524-6C301B64-B4B2-40BC-B364-A3A9F452D1D0

Q34117524-A26AF9A5-4D0A-4D6E-A8D4-D11E52426926

Q34117524-AA0DDEDA-62B2-42B2-B7C4-694BC9F7C339

Q34117524-B0C8BD6A-B991-4948-9BE8-6210D9BCBFC9

Q34117524-B9640423-2FBF-434F-9CC3-6C8E23A0CC7B

Q34117524-BE786853-F82E-4727-B454-2288E0810F99

Q34117524-C12133CA-9009-47B2-8694-3FB73F03E2AC

Q34117524-C56D184A-1471-4159-A674-7CA793C55900

Q34117524-CEE3551E-A9B7-4EC2-9FA2-B30A6FD2C979

P577

Q34117524-4C8841F2-EF31-43E7-899D-CBBC6E40B5C6

P698

Q34117524-90ABCDEF-2314-4468-8C98-546AE92C9315

P932

Q34117524-7FCB930E-6E1E-4443-852B-6B4C045EAF16

P356

P1433

Journal of Clinical Investigation

P1476

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

@en

P2093

Abraham Pinter

http://www.w3.org/2001/XMLSchema#string

Chul-Woo Pyo

http://www.w3.org/2001/XMLSchema#string

Daniel E Geraghty

http://www.w3.org/2001/XMLSchema#string

Daryl Morris

http://www.w3.org/2001/XMLSchema#string

David T Evans

http://www.w3.org/2001/XMLSchema#string

Fusheng Li

http://www.w3.org/2001/XMLSchema#string

Georgia D Tomaras

http://www.w3.org/2001/XMLSchema#string

Gustavo Kijak

http://www.w3.org/2001/XMLSchema#string

Hua-Xin Liao

http://www.w3.org/2001/XMLSchema#string

James Y Dai

http://www.w3.org/2001/XMLSchema#string

P2860

An integrated map of genetic variation from 1,092 human genomes

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

Haploview: analysis and visualization of LD and haplotype maps

Efficiency and power in genetic association studies

Toward understanding MHC disease associations: partial resequencing of 46 distinct HLA haplotypes

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

Fcgamma receptors as regulators of immune responses

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

P304

3879-3890

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI75539

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

Jaranit Kaewkungwal

Heather A Prentice

David C Montefiori

P577

2014-08-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25105367

http://www.w3.org/2001/XMLSchema#string

P932

4151214

http://www.w3.org/2001/XMLSchema#string